These small-cap biotechs have just confirmed bottom formations, setting up good buying opportunities on pullbacks.
But a few are more likely to sell than others. Here are some names.
The two drug companies end a rocky 10-year partnership. What's next for Amylin?
This biotechnology stock has the brightest growth prospects in Standard &Poor's large-cap biotech universe.
Buy any one of these mutual funds and sleep tight at night.
This biotech's Soliris drug treatment can cost $400,000 per patient.
Problems in Greece and Italy have sparked a chain reaction that is lifting health care but hammering large-cap companies with great earnings momentum.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.